<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1126" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1126/" /><meta name="ncbi_pagename" content="Oculopharyngeal Muscular Dystrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Oculopharyngeal Muscular Dystrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Oculopharyngeal Muscular Dystrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2014/02/20" /><meta name="citation_author" content="Capucine Trollet" /><meta name="citation_author" content="Teresa Gidaro" /><meta name="citation_author" content="Pierre Klein" /><meta name="citation_author" content="Sophie Périé" /><meta name="citation_author" content="Gillian Butler-Browne" /><meta name="citation_author" content="Jean Lacau St Guily" /><meta name="citation_pmid" content="20301305" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1126/" /><meta name="citation_keywords" content="OPMD" /><meta name="citation_keywords" content="OPMD" /><meta name="citation_keywords" content="Polyadenylate-binding protein 2" /><meta name="citation_keywords" content="PABPN1" /><meta name="citation_keywords" content="Oculopharyngeal Muscular Dystrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Oculopharyngeal Muscular Dystrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Capucine Trollet" /><meta name="DC.Contributor" content="Teresa Gidaro" /><meta name="DC.Contributor" content="Pierre Klein" /><meta name="DC.Contributor" content="Sophie Périé" /><meta name="DC.Contributor" content="Gillian Butler-Browne" /><meta name="DC.Contributor" content="Jean Lacau St Guily" /><meta name="DC.Date" content="2014/02/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1126/" /><meta name="description" content="Oculopharyngeal muscular dystrophy (OPMD) is characterized by ptosis and swallowing difficulties due to selective involvement of the muscles of the eyelid and pharynx, respectively. The mean age of onset of ptosis is usually 48 years and onset of dysphagia is 50 years. Early symptoms of dysphagia are increased time needed to consume a meal and an acquired avoidance of dry foods. Swallowing difficulties determine prognosis, and increase the risk for potentially life-threatening aspiration pneumonia and poor nutrition. Other signs observed as the disease progresses are tongue weakness (82%), proximal lower-extremity weakness (71%), wet voice due to pooling of saliva (67%), limitation of upward gaze (61%), facial muscle weakness (43%), and proximal upper extremity weakness (38%). Involvement of the nervous system occurs on occasion. Severe OPMD, representing 5% to 10% of all OPMD, is characterized by onset of ptosis and dysphagia before age 45 years and incapacitating proximal leg weakness that starts before age 60 years. Some individuals with severe involvement eventually need a wheelchair." /><meta name="og:title" content="Oculopharyngeal Muscular Dystrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="Oculopharyngeal muscular dystrophy (OPMD) is characterized by ptosis and swallowing difficulties due to selective involvement of the muscles of the eyelid and pharynx, respectively. The mean age of onset of ptosis is usually 48 years and onset of dysphagia is 50 years. Early symptoms of dysphagia are increased time needed to consume a meal and an acquired avoidance of dry foods. Swallowing difficulties determine prognosis, and increase the risk for potentially life-threatening aspiration pneumonia and poor nutrition. Other signs observed as the disease progresses are tongue weakness (82%), proximal lower-extremity weakness (71%), wet voice due to pooling of saliva (67%), limitation of upward gaze (61%), facial muscle weakness (43%), and proximal upper extremity weakness (38%). Involvement of the nervous system occurs on occasion. Severe OPMD, representing 5% to 10% of all OPMD, is characterized by onset of ptosis and dysphagia before age 45 years and incapacitating proximal leg weakness that starts before age 60 years. Some individuals with severe involvement eventually need a wheelchair." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1126/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/opmd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1126/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BB5D1E04140A10000000001A90099.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1126_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1126_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/oca4/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/opa/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1126_"><span class="title" itemprop="name">Oculopharyngeal Muscular Dystrophy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: OPMD</div><p class="contrib-group"><span itemprop="author">Capucine Trollet</span>, PhD, <span itemprop="author">Teresa Gidaro</span>, MD, PhD, <span itemprop="author">Pierre Klein</span>, MSc, <span itemprop="author">Sophie P&#x000e9;ri&#x000e9;</span>, MD, PhD, <span itemprop="author">Gillian Butler-Browne</span>, PhD, and <span itemprop="author">Jean Lacau St Guily</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1126_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1126_ai__"><div class="contrib half_rhythm"><span itemprop="author">Capucine Trollet</span>, PhD<div class="affiliation small">Universit&#x000e9; Pierre et Marie Curie<br />Institut de Myologie, CNRS<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.cmpu@tellort.enicupac" class="oemail">rf.cmpu@tellort.enicupac</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Teresa Gidaro</span>, MD, PhD<div class="affiliation small">Universit&#x000e9; Pierre et Marie Curie<br />Institut de Myologie, CNRS<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.eigoloym-tutitsni@oradig.t" class="oemail">gro.eigoloym-tutitsni@oradig.t</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Pierre Klein</span>, MSc<div class="affiliation small">Universit&#x000e9; Pierre et Marie Curie<br />Institut de Myologie, CNRS<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.cmpu@nielk.erreip" class="oemail">rf.cmpu@nielk.erreip</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Sophie P&#x000e9;ri&#x000e9;</span>, MD, PhD<div class="affiliation small">Service d'ORL et Chirurgie Cervico-Faciale de l&#x02019;H&#x000f4;pital Tenon (AP-HP)<br />Universit&#x000e9; Pierre et Marie Curie<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.phpa.nnt@eirep.eihpos" class="oemail">rf.phpa.nnt@eirep.eihpos</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Gillian Butler-Browne</span>, PhD<div class="affiliation small">Universit&#x000e9; Pierre et Marie Curie<br />Institut de Myologie, CNRS<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.cmpu@enworb-reltub.naillig" class="oemail">rf.cmpu@enworb-reltub.naillig</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jean Lacau St Guily</span>, MD<div class="affiliation small">Service d'ORL et Chirurgie Cervico-Faciale de l&#x02019;H&#x000f4;pital Tenon (AP-HP)<br />Universit&#x000e9; Pierre et Marie Curie<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.phpa.nnt@uacal.naej" class="oemail">rf.phpa.nnt@uacal.naej</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 8, 2001</span>; Last Update: <span itemprop="dateModified">February 20, 2014</span>.</p><p><em>Estimated reading time: 29 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="opmd.Summary" itemprop="description"><h2 id="_opmd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Oculopharyngeal muscular dystrophy (OPMD) is characterized by ptosis and swallowing difficulties due to selective involvement of the muscles of the eyelid and pharynx, respectively. The mean age of onset of ptosis is usually 48 years and onset of dysphagia is 50 years. Early symptoms of dysphagia are increased time needed to consume a meal and an acquired avoidance of dry foods. Swallowing difficulties determine prognosis, and increase the risk for potentially life-threatening aspiration pneumonia and poor nutrition. Other signs observed as the disease progresses are tongue weakness (82%), proximal lower-extremity weakness (71%), wet voice due to pooling of saliva (67%), limitation of upward gaze (61%), facial muscle weakness (43%), and proximal upper extremity weakness (38%). Involvement of the nervous system occurs on occasion. Severe OPMD, representing 5% to 10% of all OPMD, is characterized by onset of ptosis and dysphagia before age 45 years and incapacitating proximal leg weakness that starts before age 60 years. Some individuals with severe involvement eventually need a wheelchair.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>OPMD is suspected based on clinical criteria; the diagnosis is confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>PABPN1</i>. Ptosis is defined as vertical separation of at least one palpebral fissure that measures less than 8 mm at rest. Dysphagia is determined by physical examination, a videoendoscopic swallowing study (VESS), videofluoroscopic swallowing study (VFSS), and a swallowing time greater than seven seconds when drinking 80 mL of ice-cold water. Confirmatory diagnosis depends on detection of an expansion of a GCN <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> in the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> of <i>PABPN1</i>. Normal alleles contain ten GCN trinucleotide repeats. Autosomal dominant alleles range in size from 12 to 17 GCN repeats; <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> alleles comprise 11 GCN repeats. Muscle biopsy is warranted only in individuals with suspected OPMD who have two normal <i>PABPN1</i> alleles.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment for ptosis may include blepharoplasty by either resection of the levator palpebrea aponeurosis or frontal suspension of the eyelids. The common treatment for dysphagia is cricopharyngeal myotomy. However, despite the high rate of immediate improvement in swallowing with relief of dysphagia, in a very high proportion of patients progressive dysphagia recurs in the next few years.</p><p><i>Prevention of secondary complications:</i> To reduce the risk for the most common complications of OPMD (aspiration pneumonia, weight loss, and social withdrawal) the following are recommended: annual flu vaccination for the elderly; prompt evaluation of a productive cough; dietary supplements as needed to maintain weight gain; and when socializing with others, diet restricted to foods that are easily swallowed.</p><p><i>Surveillance:</i> The frequency of follow-up neurologic evaluations depends on the degree of ptosis, dysphagia, and muscle weakness; routine ophthalmologic evaluation to monitor degree of ptosis and need for surgical intervention; routine reevaluation for functional signs of dysphagia through videoscopy and fiberoscopy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>OPMD is inherited in either an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> (AD) or an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (AR) manner.</p><ul><li class="half_rhythm"><div><i>AD OPMD.</i> The proportion of OPMD caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown, but appears to be small. Each child of an individual with AD OPMD (i.e., who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for one expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the normal range [GCN 12-17]) has a 50% chance of inheriting the expanded allele and being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div><i>AR OPMD.</i> Each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. The offspring of an individual with AR OPMD are obligate heterozygotes (carriers) for a mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> causing OPMD; their risk of being affected is less than 1%.</div></li></ul><p>Prenatal testing for pregnancies at increased risk for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> OPMD is technically possible if the expanded <i>PABPN1</i> GCN repeat has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. However, requests for prenatal testing for adult-onset conditions that do not affect intellect or life span and result in relatively mild physical limitations are not common.</p></div></div><div id="opmd.Diagnosis"><h2 id="_opmd_Diagnosis_">Diagnosis</h2><div id="opmd.Clinical_Criteria"><h3>Clinical Criteria</h3><p><b>Autosomal dominant oculopharyngeal muscular dystrophy (OPMD).</b> The following three criteria are required for a diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD:</p><ul><li class="half_rhythm"><div>A positive family history with involvement of two or more generations</div></li><li class="half_rhythm"><div>The presence of ptosis defined as EITHER vertical separation of at least one palpebral fissure that measures less than 8 mm at rest OR previous corrective surgery for ptosis</div></li><li class="half_rhythm"><div>The presence of dysphagia, defined as a swallowing time greater than seven seconds when drinking 80 mL of ice-cold water [<a class="bk_pop" href="#opmd.REF.bouchard.1992.296">Bouchard et al 1992</a>]. A videoendoscopic swallowing study (VESS) and videofluoroscopic swallowing study (VFSS) are essential to document the dysfunction of the pharyngeal muscles and upper esophageal sphincter (UES) [<a class="bk_pop" href="#opmd.REF.dodds.1990.965">Dodds et al 1990</a>, <a class="bk_pop" href="#opmd.REF.langmore.1991.678">Langmore et al 1991</a>, <a class="bk_pop" href="#opmd.REF.st_guily.1995.723">St Guily et al 1995</a>, <a class="bk_pop" href="#opmd.REF.p_ri_.1998.1712">P&#x000e9;ri&#x000e9; et al 1998</a>].</div></li></ul><p><b>Autosomal recessive OPMD</b></p><ul><li class="half_rhythm"><div>The symptoms and signs are the same as for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD, but are later in onset (age &#x02265;60 years) than in the autosomal dominant form (see <a href="#opmd.Clinical_Description">Clinical Description</a>).</div></li><li class="half_rhythm"><div>Family history is consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance (i.e., <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs, unaffected parents, and/or parental <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>).</div></li></ul></div><div id="opmd.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p>Molecular genetic testing of <i>PABPN1</i> is used to confirm the diagnosis in individuals known or suspected to have OPMD (see <a class="figpopup" href="/books/NBK1126/figure/opmd.F1/?report=objectonly" target="object" rid-figpopup="figopmdF1" rid-ob="figobopmdF1">Figure 1</a>). A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is defined as a larger than normal "GCN" <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> in the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> of <i>PABPN1</i> (previously called <i>PABP2</i>) [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>] (<a class="figpopup" href="/books/NBK1126/table/opmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figopmdTmoleculargenetictestingusedin" rid-ob="figobopmdTmoleculargenetictestingusedin">Table 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figopmdF1" co-legend-rid="figlgndopmdF1"><a href="/books/NBK1126/figure/opmd.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figopmdF1" rid-ob="figobopmdF1"><img class="small-thumb" src="/books/NBK1126/bin/opmd-Image001.gif" src-large="/books/NBK1126/bin/opmd-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndopmdF1"><h4 id="opmd.F1"><a href="/books/NBK1126/figure/opmd.F1/?report=objectonly" target="object" rid-ob="figobopmdF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Diagnostic evaluation of dysphagia and ptosis </p></div></div><p>Note: Because four different codons &#x02012; GCA, GCT, GCC, and GCG &#x02012; encode the amino acid alanine, GCN, where N represents any A/C/G/T nucleotide, is a generic designation for these four possible codons. A recent European Neuromuscular Center (ENMC) workshop on OPMD [<a class="bk_pop" href="#opmd.REF.raz.2013.516">Raz et al 2013</a>] suggested the following nomenclature for number of triplet repeats/number of alanine of <i>PABPN1</i> variants:</p><ul><li class="half_rhythm"><div>Normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>: (GCN)10 / Ala10</div></li><li class="half_rhythm"><div>Pathogenic alleles: (GCN)11-17 and Ala11&#x02013;17, where the range of triplet repeats/alanines is 11-17</div></li></ul><p>When available, the full sequence of normal and pathogenic alleles should be reported; for example, an Ala13 <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may have a sequence of (GCG)10(GCA)(GCG)2.</p><p>The nomenclature of the Human Genome Variation Society for these alleles is summarized in <a href="#opmd.Molecular_Genetics">Molecular Genetics</a>.</p><p><b>Normal alleles</b> have ten GCN repeats (GCN)10 (previously referred to as the (GCG)6 normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) encoding ten alanines (Ala10).</p><p>Note: <i>PABPN1</i> variants were first described as pure (GCG) expansions of a (GCG)<sub>6</sub> stretch coding for six alanines in the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>]. However, approximately 25% of these variants consist of (GCN) repeats [<a class="bk_pop" href="#opmd.REF.nakamoto.2002.474">Nakamoto et al 2002</a>], each encoding alanine.</p><p><b>Autosomal dominant alleles</b> have 12 to 17 GCN repeats. In one study [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>], probands had <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> frequencies of</p><ul><li class="half_rhythm"><div>5% (GCN)12/Ala12</div></li><li class="half_rhythm"><div>40% (GCN)13/Ala13</div></li><li class="half_rhythm"><div>26% (GCN)14/Ala14</div></li><li class="half_rhythm"><div>21% (GCN)15/Ala15</div></li><li class="half_rhythm"><div>7% (GCN)16/Ala16</div></li><li class="half_rhythm"><div>1% (GCN)17/Ala17</div></li></ul><p><b>Autosomal recessive alleles</b> have 11 GCN repeats (GCN)11/Ala11 (i.e., previously referred to as (GCN)7). Autosomal recessive inheritance has only been observed in one instance in an individual <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for (GCN)11 alleles [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>].</p><div id="opmd.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Oculopharyngeal Muscular Dystrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1126/table/opmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opmd.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic Variant</th><th id="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PABPN1</i></td><td headers="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>2</sup></td><td headers="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heterozygosity for (GCN)<sub>12-17</sub></td><td headers="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Homozygosity for (GCN)<sub>11</sub></td><td headers="hd_h_opmd.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%, recessive&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="opmd.TF.1.1"><p class="no_margin">See <a href="/books/NBK1126/#opmd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#opmd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>2. </dt><dd><div id="opmd.TF.1.2"><p class="no_margin">Testing to determine the size of the GCN <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> in the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> of <i>PABPN1</i> is more than 99% sensitive and 100% specific.</p></div></dd><dt>3. </dt><dd><div id="opmd.TF.1.3"><p class="no_margin">Growing evidence indicates that &#x0003e;99% of individuals with a severe <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have a <i>PABPN1</i> (GCN) expansion.</p></div></dd><dt>4. </dt><dd><div id="opmd.TF.1.4"><p class="no_margin">One case reported [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>]</p></div></dd></dl></div></div></div></div><div id="opmd.Additional_Testing"><h3>Additional Testing</h3><p><b>Muscle biopsy.</b> Previously the diagnosis of OPMD was based on the presence of intranuclear inclusions (INI) on muscle biopsy; currently muscle biopsy is only warranted in individuals who have two normal <i>PABPN1</i> alleles.</p><ul><li class="half_rhythm"><div>INI, considered a specific histologic hallmark of OPMD, consist of tubular filaments [<a class="bk_pop" href="#opmd.REF.tom_.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</a>] that are up to 250 nm in length and have an external diameter of 8.5 nm and an internal diameter of 3 nm. Of the nuclei seen in every ultra-thin section of deltoid muscle by electron microscopy, 4%-5% contain INI [<a class="bk_pop" href="#opmd.REF.tom_.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</a>]. With use of a different technique (KCl-pretreatment followed by PABPN1 immunostaining), the percentage of INI was recently estimated at between 2% and 15% of myonuclei in OPMD muscles [<a class="bk_pop" href="#opmd.REF.gidaro.2013.234">Gidaro et al 2013</a>].</div></li><li class="half_rhythm"><div>To date, OPMD INI differ from other types of intranuclear inclusions described in other muscle disorders [<a class="bk_pop" href="#opmd.REF.tom_.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</a>], such as the 15-18 nm filaments described in the nucleus and cytoplasm in individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> inclusion body myositis (IBM) [<a class="bk_pop" href="#opmd.REF.coquet.1990.393">Coquet et al 1990</a>].</div></li></ul><p>Besides the INI, all biopsies from clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or unaffected OPMD muscles show dystrophic changes: variation in the diameter of muscle fibers, atrophic angulated muscle fibers, ragged red fibers, and rimmed vacuoles [<a class="bk_pop" href="#opmd.REF.tom_.1994">Tom&#x000e9; &#x00026; Fardeau 1994</a>, <a class="bk_pop" href="#opmd.REF.gidaro.2013.234">Gidaro et al 2013</a>]. Note that although the presence of rimmed vacuoles may be useful for diagnosis of OPMD, they are not present in all OPMD muscle biopsies [<a class="bk_pop" href="#opmd.REF.fukuhara.1980.229">Fukuhara et al 1980</a>]; nor are rimmed vacuoles specific for OPMD: they have been consistently found in several other muscular diseases; for example, in IBM [<a class="bk_pop" href="#opmd.REF.askanas.1995.486">Askanas &#x00026; Engel 1995</a>], where they are much more numerous than in OPMD [<a class="bk_pop" href="#opmd.REF.leclerc.1993.283">Leclerc et al 1993</a>].</p><p><b>Electromyography (EMG)</b> of weak muscles usually reveals discrete signs of a myopathic process [<a class="bk_pop" href="#opmd.REF.bouchard.1997.s22">Bouchard et al 1997</a>]. Very mild neuropathic findings have been reported, but are thought to be related in most cases to old age or concomitant disease. EMG is not necessary for OPMD diagnosis because it is clinically nonspecific.</p><p><b>Serum CK</b> concentrations elevated two to seven times above the normal value have been reported in individuals with OPMD with severe leg weakness [<a class="bk_pop" href="#opmd.REF.barbeau.1996">Barbeau 1996</a>]. In most cases, however, serum CK concentration is normal or up to twice the upper normal value. CK level is not relevant for the diagnosis or follow up of persons with OPMD.</p></div></div><div id="opmd.Clinical_Characteristics"><h2 id="_opmd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="opmd.Clinical_Description"><h3>Clinical Description</h3><p>Oculopharyngeal muscular dystrophy (OPMD) is characterized by late-onset involvement of small distinct muscles of the eyelid (levator palpebrae superioris muscle) causing ptosis and of the pharynx causing dysphagia. Ptosis and dysphagia usually become manifest around the fifth decade. Disease progression is slow.</p><p>Ptosis is always bilateral, but may be asymmetric, at least in the early stage of disease [<a class="bk_pop" href="#opmd.REF.brais.2003.252">Brais 2003</a>]. Individuals with severe bilateral ptosis may compensate for visual field limitation with &#x0201c;astrologist&#x02019;s posture,&#x0201d; retroflexion of the neck and downward gaze combined with contraction of the frontalis muscles [<a class="bk_pop" href="#opmd.REF.r_egg.2005.574">R&#x000fc;egg et al 2005</a>].</p><p>Dysphagia is detected first for solid foods, later also for liquids. The degenerative dystrophy and progressive onset of fibrosis in the pharyngeal muscles create difficulties in propulsing the food bolus in the pharynx. This together with a decreased relaxation of the cricopharyngeal muscle (the main muscle of the upper esophageal sphincter (UES) located between the pharynx and the esophagus) result in a delay in the transfer of the bolus through the UES.</p><p>Of note, while in the past dysphagia resulted in poor nutrition that usually caused death by starvation, recent progress (especially in the treatment of pharyngeal dysfunction) has improved the quality of life for persons with OPMD.</p><p>Extraocular muscles may become gradually <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but complete external ophthalmoplegia is rare [<a class="bk_pop" href="#opmd.REF.tom_.1994">Tom&#x000e9; &#x00026; Fardeau 1994</a>].</p><p>Weakness and atrophy can occur in limb girdle muscles (shoulder girdle muscles more than pelvic girdle muscles). Limb muscle involvement is symmetric and nonselective.</p><p>Distal muscle weakness has been described in a Japanese family [<a class="bk_pop" href="#opmd.REF.goto.1977.600">Goto et al 1977</a>, <a class="bk_pop" href="#opmd.REF.satoyoshi.1977.89">Satoyoshi &#x00026; Kinoshita 1977</a>] and in other ethnic groups [<a class="bk_pop" href="#opmd.REF.jaspar.1977.272">Jaspar et al 1977</a>, <a class="bk_pop" href="#opmd.REF.scrimgeour.1984.763">Scrimgeour &#x00026; Mastaglia 1984</a>]; however, distal muscle involvement has not been associated with typical OPMD [<a class="bk_pop" href="#opmd.REF.schotland.1964.433">Schotland &#x00026; Rowland 1964</a>, <a class="bk_pop" href="#opmd.REF.vita.1983.57">Vita et al 1983</a>].</p><p>Although OPMD is considered a primary muscle disorder, in rare instances peripheral nervous system involvement has been described. The first of such reported cases presented a severe depletion of myelinated fibers in endomysial nerve twigs of extraocular, pharyngeal, and lingual muscles pointing to neurogenic changes in these muscles and suggesting nerve involvement [<a class="bk_pop" href="#opmd.REF.probst.1982.209">Probst et al 1982</a>, <a class="bk_pop" href="#opmd.REF.schober.2001.45">Schober et al 2001</a>]. Other cases have also shown central nervous system involvement [<a class="bk_pop" href="#opmd.REF.linoli.1991.325">Linoli et al 1991</a>]. <a class="bk_pop" href="#opmd.REF.dubbioso.2012.833">Dubbioso et al [2012]</a> described an individual with central nervous system involvement with impaired executive functions.</p><p><b>Autosomal dominant OPMD.</b> The age of onset of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD varies and is often difficult to pinpoint. In a study of 72 symptomatic individuals of French-Canadian ancestry with a (GCN)13 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the mean age of onset for ptosis was 48.1 years (range 26-65 years) and for dysphagia, 50.7 years (range 40-63 years).</p><p>Early symptoms suggestive of dysphagia caused by OPMD are increased time needed to consume a meal and an acquired avoidance of dry foods. Other signs observed as the disease progresses are tongue atrophy and weakness (82%), proximal lower-extremity weakness (71%), wet voice due to pooling of saliva (67%), limitation of upward gaze (61%), facial muscle weakness (43%), and proximal upper-extremity weakness (38%) [<a class="bk_pop" href="#opmd.REF.bouchard.1997.s22">Bouchard et al 1997</a>].</p><p>Disease severity varies. Severe disease, representing 5% to 10% of all OPMD, is characterized by onset of ptosis and dysphagia before age 45 years; incapacitating proximal leg weakness starts before age 60 years. Some eventually need a wheelchair.</p><p>Although OPMD does not appear to reduce life span, quality of life in later years is greatly diminished [<a class="bk_pop" href="#opmd.REF.becher.2001.2437">Becher et al 2001</a>]. Of note, the severity of dysphagia determines the prognosis, as it leads to potentially life-threatening aspiration pneumonia and poor nutrition.</p><p><b>Autosomal recessive OPMD.</b> Ptosis and dysphagia occur after age 60 years. Some evidence suggests that <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> carriers of the recessive (GCG)7 <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may be at higher risk of developing dysphagia after age 70 years.</p></div><div id="opmd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The variability of age of onset and severity of weakness may depend on the number of (GCN) repeats; this important issue is as yet unresolved.</p><p><b>Severe <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD.</b> Of the 5% to 10% of all individuals with autosomal dominant OPMD who have severe disease:</p><ul><li class="half_rhythm"><div>20% are compound heterozygotes for an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the (GCN)12-17 range and an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> allele of (GCN)11 [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>]. While (GCN)11 homozygosity is known to lead to autosomal recessive OMPD, in this scenario it acts as a severity modifier of a dominant OMPD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, presumably because more mutated proteins are produced. The (GCN)11 <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency is 1% to 2% of North American, European, and Japanese populations.</div></li><li class="half_rhythm"><div>In 80% the reason for the increased disease severity is unknown. Of note, severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals cluster in families, a phenomenon suggesting that other genetic factors modulate severity.</div></li></ul><p><b>Homozygous <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD.</b> The most severe OPMD presentation is reported in individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for an autosomal dominant OPMD <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#opmd.REF.blumen.1996.1324">Blumen et al 1996</a>, <a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>, <a class="bk_pop" href="#opmd.REF.blumen.1999.115">Blumen et al 1999</a>]. A study of four French-Canadian and three Bukhara Jewish OPMD homozygotes documented that on average the onset was 18 years earlier than in (GCN)13 heterozygotes.</p><p><b>Autosomal recessive OPMD</b> (i.e., caused by homozygosity for (GCN)11 alleles) has a later onset and milder disease than <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD.</p></div><div id="opmd.Penetrance"><h3>Penetrance</h3><p>Decade-specific cumulative <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for individuals with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> (GCN)13 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#opmd.REF.brais.1997.s70">Brais et al 1997</a>]:</p><ul><li class="half_rhythm"><div>Age &#x0003c;40 years: 1%</div></li><li class="half_rhythm"><div>Age 40-49 years: 6%</div></li><li class="half_rhythm"><div>Age 50-59 years: 31%</div></li><li class="half_rhythm"><div>Age 60-69 years: 63%</div></li><li class="half_rhythm"><div>Age &#x0003e;69 years: 99%</div></li></ul><p>Thus, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OPMD resulting from (GCN)13 heterozygosity is fully penetrant after age 70 years.</p></div><div id="opmd.Anticipation"><h3>Anticipation</h3><p>The GCN/alanine triplet repeat in <i>PABPN1</i> is mitotically and meiotically stable. Therefore, expansion of the triplet repeat in meiosis is rare. Clinical <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> is not observed with this disease. The estimated secondary mutation of an existent dominant <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is on the order of 1:500 meioses [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>].</p></div><div id="opmd.Prevalence"><h3>Prevalence</h3><p><b>Autosomal dominant.</b> The prevalence of OPMD has been estimated at 1:100,000 in France, 1:1000 in the French-Canadian population of the province of Quebec, and 1:600 among Bukhara Jews living in Israel [<a class="bk_pop" href="#opmd.REF.brais.1995.429">Brais et al 1995</a>, <a class="bk_pop" href="#opmd.REF.blumen.1997.s38">Blumen et al 1997</a>, <a class="bk_pop" href="#opmd.REF.brunet.1997.s34">Brunet et al 1997</a>]. In the United States, the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are of French-Canadian extraction, though a large number are also of other backgrounds, including Jewish Ashkenazi [<a class="bk_pop" href="#opmd.REF.victor.1962.1267">Victor et al 1962</a>] and Spanish American in Texas [<a class="bk_pop" href="#opmd.REF.becher.2001.2437">Becher et al 2001</a>] and California [<a class="bk_pop" href="#opmd.REF.grewal.1999.1378">Grewal et al 1999</a>].</p><p>Autosomal dominant OPMD has been identified in individuals from more than 30 countries.</p><p><b>Autosomal recessive.</b> The predicted prevalence of the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> form should be in the order of 1:10,000 in France, Quebec, and Japan based on the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of the (GCN)11 autosomal recessive <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in these populations [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>].</p></div></div><div id="opmd.Genetically_Related_Allelic_Disorde"><h2 id="_opmd_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of PABPN1.</p></div><div id="opmd.Differential_Diagnosis"><h2 id="_opmd_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis should include all late-onset neuromuscular diseases characterized by swallowing difficulties and/or ptosis (see <a class="figpopup" href="/books/NBK1126/figure/opmd.F1/?report=objectonly" target="object" rid-figpopup="figopmdF1" rid-ob="figobopmdF1">Figure 1</a>):</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/myotonic-d/"><b>Myotonic dystrophy type 1</b></a> (caused by an expansion of the CTG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> in <i>DMPK</i> and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/myotonic-d2/"><b>Myotonic muscular dystrophy type 2</b></a> (caused by a CCTG tetranucleotide repeat expansion in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 of <i>CNBP</i> and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner)</div></li><li class="half_rhythm"><div><b>Autosomal dominant distal myopathy</b></div><ul><li class="half_rhythm"><div>Distal hereditary motor neuropathy type VII (HMN7A; Harper-Young myopathy) (OMIM <a href="http://www.omim.org/entry/158580" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">158580</a>), caused by mutation of <i>SLC5A7</i>. In these families spinal muscular atrophy is accompanied by vocal cord and pharyngeal weakness without ptosis [<a class="bk_pop" href="#opmd.REF.young.1980.413">Young &#x00026; Harper 1980</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#opmd.REF.feit.1998.1732">Feit et al [1998]</a> described a distal myopathy with a similar <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of vocal cord and pharyngeal dysfunction (OMIM <a href="http://www.omim.org/entry/606070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606070</a>), caused by mutation of <i>MATR3</i>.</div></li></ul></li><li class="half_rhythm"><div><a href="/books/n/gene/mt-overview/"><b>Mitochondrial myopathy</b></a> with or without progressive external ophthalmoplegia (PEO) including <a href="/books/n/gene/mngie/">mitochondrial neurogastrointestinal encephalomyopathy disease</a> (MNGIE syndrome)</div></li><li class="half_rhythm"><div><b>Myasthenia gravis</b> (OMIM <a href="http://www.omim.org/entry/254200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">254200</a>). The absence of family history and the fluctuation of symptoms in myasthenia gravis usually distinguish the two conditions. If in doubt, electromyography and neostigmine testing can confirm the diagnosis of myasthenia gravis, and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can confirm the diagnosis of OPMD.</div></li><li class="half_rhythm"><div><b>Inclusion body myositis, polymyositis, and progressive bulbar palsy.</b> These conditions do not have ptosis.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/bpes/"><b>Blepharophimosis, ptosis, and epicanthus inversus</b></a>
<b>(BPES).</b> In this condition, the ptosis is usually <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>, it is always associated with epicanthus inversus, and dysphagia is not a feature.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/cfeom/"><b>Congenital fibrosis of the extraocular muscles</b></a>
<b>(CFEOM).</b> In this condition, the ptosis is <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> and dysphagia is not a feature.</div></li><li class="half_rhythm"><div><b>Other.</b> At least one other dominant OPMD-like condition, which is more severe and is not caused by GCN expansion in <i>PABPN1</i>, appears to exist [<a class="bk_pop" href="#opmd.REF.hill.2004.cd004303">Hill et al 2004</a>].</div></li></ul><p><b>Oculopharyngodistal myopathy</b> (OMIM <a href="http://www.omim.org/entry/164310" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">164310</a>) is still a poorly characterized condition in which dysphagia, ptosis, and distal weakness appear earlier in the twenties than in OPMD. The mode of transmission is still unclear; both dominant and recessive modes have been proposed. Pathologically, no intranuclear inclusions are observed and no <i>PABPN1</i> (GCN) pathogenic variants are observed [<a class="bk_pop" href="#opmd.REF.van_der_sluijs.2004.1499">van der Sluijs et al 2004</a>].</p></div><div id="opmd.Management"><h2 id="_opmd_Management_">Management</h2><div id="opmd.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and the needs of an individual diagnosed with oculopharyngeal muscular dystrophy (OPMD), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Evaluation for swallowing difficulties by history and in more severe cases with a videoendoscopic swallowing study (VESS) and/or videofluoroscopic swallowing study (VFSS) [<a class="bk_pop" href="#opmd.REF.dodds.1990.965">Dodds et al 1990</a>, <a class="bk_pop" href="#opmd.REF.langmore.1991.678">Langmore et al 1991</a>, <a class="bk_pop" href="#opmd.REF.st_guily.1995.723">St Guily et al 1995</a>, <a class="bk_pop" href="#opmd.REF.p_ri_.1998.1712">P&#x000e9;ri&#x000e9; et al 1998</a>].</div><ul><li class="half_rhythm"><div>VESS gives indirect signs of upper esophageal sphincter (UES) dysfunction</div></li><li class="half_rhythm"><div>VFSS gives a direct evaluation of the UES using radiopaque barite in the tracheobronchial tree</div></li><li class="half_rhythm"><div>The drink test, a global quantitative functional evaluation of swallowing, is abnormal when it takes longer than seven seconds to drink 80 mL of ice-cold water [<a class="bk_pop" href="#opmd.REF.bouchard.1992.296">Bouchard et al 1992</a>, <a class="bk_pop" href="#opmd.REF.brais.1995.429">Brais et al 1995</a>]. Questionnaires can also be used to evaluate the degree of dysphagia (i.e., the Mc Horney score [<a class="bk_pop" href="#opmd.REF.mchorney.2002.97">McHorney et al 2002</a>] and the Salassa grade [<a class="bk_pop" href="#opmd.REF.salassa.1999.230">Salassa 1999</a>].</div></li></ul></li><li class="half_rhythm"><div>Neuromuscular examination performed by a neurologist to determine overall disease progression and the presence (and severity) of ptosis, dysphagia, proximal weakness, and the presence or absence of any other neurologic findings</div></li><li class="half_rhythm"><div>Consideration of muscle biopsy in those cases with more severe or complicated presentations</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="opmd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Ptosis</b></p><p>Surgery is recommended when ptosis interferes with vision or appears to cause cervical pain secondary to constant dorsiflexion of the neck. The two types of blepharoplasty used to correct the ptosis are resection of the levator palpebrae aponeurosis and frontal suspension of the eyelids [<a class="bk_pop" href="#opmd.REF.cod_re.1993.1">Cod&#x000e8;re 1993</a>].</p><ul><li class="half_rhythm"><div>Resection of the aponeurosis is easily done, but usually needs to be repeated once or twice [<a class="bk_pop" href="#opmd.REF.rodrigue.1997.s82">Rodrigue &#x00026; Molgat 1997</a>].</div></li><li class="half_rhythm"><div>Frontal suspension of the eyelids uses a thread of muscle fascia as a sling; the fascia is inserted through the tarsal plate of the upper eyelid and the ends are attached in the frontalis muscle, which is relatively preserved in OPMD [<a class="bk_pop" href="#opmd.REF.cod_re.1993.1">Cod&#x000e8;re 1993</a>]. The major advantage of frontal suspension of the eyelids is that it is permanent; however, the procedure requires general anesthesia.</div></li></ul><p><b>Dysphagia</b></p><ul><li class="half_rhythm"><div>Food should be cut into small pieces.</div></li><li class="half_rhythm"><div>Although no controlled trials have been performed [<a class="bk_pop" href="#opmd.REF.hill.2004.cd004303">Hill et al 2004</a>], surgical intervention for dysphagia should be considered when symptomatic dysphagia is accompanied by marked weight loss, near-fatal choking, and/or recurrent pneumonia [<a class="bk_pop" href="#opmd.REF.duranceau.1983.825">Duranceau et al 1983</a>, <a class="bk_pop" href="#opmd.REF.st_guily.1995.723">St Guily et al 1995</a>, <a class="bk_pop" href="#opmd.REF.p_ri_.1997.s96">P&#x000e9;ri&#x000e9; et al 1997</a>, <a class="bk_pop" href="#opmd.REF.coiffier.2006.218">Coiffier et al 2006</a>].</div></li><li class="half_rhythm"><div>Cricopharyngeal myotomy, consisting of extramucosal section of the cricopharyngeal muscle that improves swallowing through the upper esophageal sphincter [<a class="bk_pop" href="#opmd.REF.montgomery.1971.986">Montgomery &#x00026; Lynch 1971</a>, <a class="bk_pop" href="#opmd.REF.duranceau.1980.33">Duranceau et al 1980</a>, <a class="bk_pop" href="#opmd.REF.st_guily.1994.34">St Guily et al 1994</a>, <a class="bk_pop" href="#opmd.REF.st_guily.1995.723">St Guily et al 1995</a>, <a class="bk_pop" href="#opmd.REF.duranceau.1997.s85">Duranceau 1997</a>], is easily performed and immediately improves symptoms in most cases [<a class="bk_pop" href="#opmd.REF.duranceau.1983.825">Duranceau et al 1983</a>]; however, in a very high proportion of patients progressive dysphagia recurs within years [<a class="bk_pop" href="#opmd.REF.coiffier.2006.218">Coiffier et al 2006</a>].</div></li></ul></div><div id="opmd.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>The major complications of OPMD are aspiration pneumonia, weight loss, and social withdrawal because of frequent choking while eating. To reduce the risk for these complications:</p><ul><li class="half_rhythm"><div>Annual flu vaccination is recommended for elderly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div></li><li class="half_rhythm"><div>Consultation should be sought promptly for a productive cough because of the increased risk for lung abscesses.</div></li><li class="half_rhythm"><div>Dietary supplements should be added if weight loss is significant.</div></li><li class="half_rhythm"><div>In social settings involving food consumption, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should either avoid eating or choose foods that are easy to swallow.</div></li></ul><p>General anesthesia is not contraindicated even though individuals with OPMD may respond differently to certain anesthetics [<a class="bk_pop" href="#opmd.REF.caron.2005.393">Caron et al 2005</a>].</p></div><div id="opmd.Surveillance"><h3>Surveillance</h3><p>The frequency of follow-up neurologic evaluations depends on the degree of ptosis, dysphagia, and muscle weakness.</p><p>Perform routine ophthalmologic evaluation o determine if ptosis interferes with driving or is associated with neck pain, and or if the eyelids cover more than 50% of the pupil, findings that might lead to consideration of surgical intervention.</p><p>Perform routine reevaluation for functional signs of dysphagia using videoscopy and fiberoscopy.</p></div><div id="opmd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#opmd.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="opmd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Repetitive dilatations of the upper-esophageal sphincter with bougies [<a class="bk_pop" href="#opmd.REF.mathieu.1997.s100">Mathieu et al 1997</a>, <a class="bk_pop" href="#opmd.REF.manjaly.2012.216">Manjaly et al 2012</a>] and botulinum toxin injection of the cricopharyngeal muscle [<a class="bk_pop" href="#opmd.REF.restivo.2000.1416">Restivo et al 2000</a>] have been suggested as treatment for dysphagia.</p><p>An autologous cell transplantation clinical Phase I/IIa study (ClinicalTrials.gov <a href="http://clinicaltrials.gov/ct2/show/NCT00773227?term=NCT00773227&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT00773227</a>) has also been recently described [<a class="bk_pop" href="#opmd.REF.p_ri_.2014.219">P&#x000e9;ri&#x000e9; et al 2014</a>]. The trial was based on the observation that cells isolated from unaffected muscles of persons with OPMD are able to proliferate and differentiate normally, whereas cells isolated from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> muscles have reduced myogenicity (ability to proliferate and differentiate normally) [<a class="bk_pop" href="#opmd.REF.p_ri_.2006.770">P&#x000e9;ri&#x000e9; et al 2006</a>]. The therapeutic strategy is to isolate muscle progenitors (myoblasts) from clinically unaffected muscles of persons with OPMD and implant them into dystrophic pharyngeal muscles to reinforce their motor ability and restore contractility and, thus, reduce the dysphagia. The conclusions of this trial on 12 patients with OPMD support the hypothesis that an injection of autologous myoblasts into pharyngeal muscles is a safe and efficient procedure [<a class="bk_pop" href="#opmd.REF.p_ri_.2014.219">P&#x000e9;ri&#x000e9; et al 2014</a>].</p><p>In cellular models of OPMD, investigators have reduced cellular toxicity by inducing heat shock protein expression using ZnSO4, 8-hydroxyquinoline, ibuprofen, and indomethacin [<a class="bk_pop" href="#opmd.REF.wang.2005.3673">Wang et al 2005</a>] or exposing cells to an anti-PABPN1 single-<a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> antibody called intrabody that interferes with oligomerization [<a class="bk_pop" href="#opmd.REF.verheesen.2006.105">Verheesen et al 2006</a>]. These intrabodies also reduced intranuclear inclusion (INI) formation and symptoms related to OPMD in a drosophila OPMD model [<a class="bk_pop" href="#opmd.REF.chartier.2009.1849">Chartier et al 2009</a>].</p><p>More recently, investigators have tested molecules that interfere with the Wnt/beta-catenin pathway such as lithium chloride [<a class="bk_pop" href="#opmd.REF.abubaker.2013.e821">Abu-Baker et al 2013</a>].</p><p>In a transgenic mouse model of OPMD, investigators have reduced inclusion formation and cell death with agents that interfere with protein aggregation such as doxycycline [<a class="bk_pop" href="#opmd.REF.davies.2005.672">Davies et al 2005</a>] and trehalose [<a class="bk_pop" href="#opmd.REF.davies.2006.23">Davies et al 2006</a>].These studies suggest that therapeutic trials in OPMD are possible given that some of the tested molecules have already been given to humans.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="opmd.Genetic_Counseling"><h2 id="_opmd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="opmd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Oculopharyngeal muscular dystrophy is inherited in either an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="opmd.Autosomal_Dominant_OPMD__Risk_to_Fa"><h3>Autosomal Dominant OPMD &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with OPMD have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Note: In rare instances of a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, both parents will be affected (see <b>Offspring of a proband</b>, <b>Homozygotes</b>)</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with OPMD may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> pathogenic variant is unknown but appears to be small.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li></ul><p>Note: Although most individuals diagnosed with OPMD have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the status of the parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an expanded (GCN) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the risk to the sibs of inheriting the expanded allele is 50%.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div><b>Heterozygotes.</b> Each child of an individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for one expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (GCN)12-17 has a 50% chance of inheriting the expanded allele.</div></li><li class="half_rhythm"><div><b>Homozygotes.</b> A few individuals (French-Canadians and members of the inbred population of Bukhara Jews living in Israel [<a class="bk_pop" href="#opmd.REF.blumen.1999.115">Blumen et al 1999</a>]) who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the expanded alleles (GCN)13 have been described. All offspring of such an individual are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li></ul><p><b>Other family members of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the genetic status of the proband's parents. If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the proband's family members are at risk.</p></div><div id="opmd.Autosomal_Recessive_OPMD"><h3>Autosomal Recessive OPMD</h3><div id="opmd.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p>One individual <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the (GCN)11 <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been reported [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>]. This individual has been referred to as having <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> OPMD. Because the (GCN)11 allele has a 1% to 2% prevalence, other persons who are homozygous for this allele with a mild OPMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be unrecognized because of a negative family history.</p><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes and therefore carry one expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are usually asymptomatic.</div></li><li class="half_rhythm"><div>Parents of individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> OPMD are unlikely to be alive at the time of diagnosis of their child and should not have been <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the chance of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are usually asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> OPMD are obligate heterozygotes (carriers) for an expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> causing autosomal recessive OPMD. The risk of the child being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> is less than 1%.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Sibs of the proband's parents are at 50% risk of also being carriers.</p></div><div id="opmd.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing is possible once the diagnosis has been established in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. See <a href="#opmd.Molecular_Genetic_Testing">Molecular Genetic Testing</a>.</p></div></div><div id="opmd.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Specific risk issues.</b> Individuals inheriting an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> from an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent and an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> expanded allele [(GCN)11] from the other parent will develop a severe form of OPMD (see <a href="#opmd.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Testing of at-risk asymptomatic adults</b> for OPMD is possible using the techniques described in <a href="#opmd.Molecular_Genetic_Testing">Molecular Genetic Testing</a>. Such testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. When testing at-risk individuals for OPMD, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member should be tested first to confirm the molecular diagnosis in the family.</p><p><b>Molecular genetic testing of asymptomatic individuals younger than age 18 years</b> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p><p>Genetic testing is indicated in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or symptomatic individuals in a family with established OPMD regardless of age.</p><p>See also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="opmd.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for OPMD are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="opmd.Resources"><h2 id="_opmd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association Francaise contre les Myopathies (AFM)</b></div><div>1 Rue de l'International</div><div>BP59</div><div>Evry cedex 91002</div><div>France</div><div><b>Phone:</b> +33 01 69 47 28 28</div><div><b>Email:</b> dmc@afm.genethon.fr</div><div><a href="http://www.afm-telethon.fr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.afm-telethon.fr </a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - Canada</b></div><div>2345 Yonge Street</div><div>Suite 900</div><div>Toronto Ontario M4P 2E5</div><div>Canada</div><div><b>Phone:</b> 866-687-2538 (toll-free); 416-488-0030</div><div><b>Fax:</b> 416-488-7523</div><div><b>Email:</b> info@muscle.ca</div><div><a href="http://www.muscle.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.muscle.ca</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy UK</b></div><div>61A Great Suffolk Street</div><div>London SE1 0BU </div><div>United Kingdom</div><div><b>Phone:</b> 0800 652 6352 (toll-free); 020 7803 4800</div><div><b>Email:</b> info@musculardystrophyuk.org</div><div><a href="http://www.musculardystrophyuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.musculardystrophyuk.org</a></div></li></ul></div><div id="opmd.Molecular_Genetics"><h2 id="_opmd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="opmd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Oculopharyngeal Muscular Dystrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1126/table/opmd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opmd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_opmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_opmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_opmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_opmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_opmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_opmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_opmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8106" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PABPN1</i></a></td><td headers="hd_b_opmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8106" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q11<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_opmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q86U42" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Polyadenylate-binding protein 2</a></td><td headers="hd_b_opmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/PABPN1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PABPN1 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_opmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PABPN1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PABPN1</a></td><td headers="hd_b_opmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PABPN1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PABPN1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="opmd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="opmd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Oculopharyngeal Muscular Dystrophy (<a href="/omim/164300,602279" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1126/table/opmd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opmd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/164300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602279" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602279</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POLYADENYLATE-BINDING PROTEIN, NUCLEAR, 1; PABPN1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>PABPN1</i> has seven exons. The role of the two long introns preserved in many of its mRNAs is unknown. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1126/#opmd.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Normal <i>PABPN1</i> alleles have (GCN)10 encoding Ala10 residues.</p><p>Note on nomenclature: This <i>GeneReview</i> follows the nomenclature recommended by the European Neuromuscular Center (ENMC) workshop on OPMD [<a class="bk_pop" href="#opmd.REF.raz.2013.516">Raz et al 2013</a>, <a href="http://www.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Genome Variation Society</a>].</p><p><b>Pathogenic variants.</b> See <a href="#opmd.Molecular_Genetic_Testing">Molecular Genetic Testing</a>. The OPMD pathogenic alleles have an expanded (GCN) sequence that immediately follows the start codon ATG. As in other disorders caused by (CAG)/polyglutamine expansion, it is the absolute size of the <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that is the size of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and not the size of the added expansions. It is not known for certain if the mutation mechanism is expansion of the GCN repeat through slippage or <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of additional (GCN)s through unequal <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> or <a class="def" href="/books/n/gene/glossary/def-item/gene-conversion/">gene conversion</a> events [<a class="bk_pop" href="#opmd.REF.chen.2005.125">Chen et al 2005</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> PABPN1 protein has at least the following six domains: polyalanine, coil-coiled, RNA binding, two oligomerization, and a nuclear localization signal (NLS) [<a class="bk_pop" href="#opmd.REF.calado.2000.2321">Calado et al 2000</a>, <a class="bk_pop" href="#opmd.REF.fan.2001.2341">Fan et al 2001</a>, <a class="bk_pop" href="#opmd.REF.k_hn.2003.16916">K&#x000fc;hn et al 2003</a>]. PABPN1 is an abundant nuclear protein of approsimately 49 kd that binds with high affinity to nascent poly(A) tails at the 3' end of mRNAs [<a class="bk_pop" href="#opmd.REF.wahle.1993.2937">Wahle et al 1993</a>, <a class="bk_pop" href="#opmd.REF.nemeth.1995.4034">Nemeth et al 1995</a>]. The poly(A) tail is post-transcriptionally added to the <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> by a number of <a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a>-acting factors including PABPN1, the cleavage and polyadenylation specificity factor (CPSF), and the poly(A) polymerase (PAP) [<a class="bk_pop" href="#opmd.REF.wahle.1999.277">Wahle &#x00026; R&#x000fc;egsegger 1999</a>, <a class="bk_pop" href="#opmd.REF.zhao.1999.405">Zhao et al 1999</a>].</p><p>It was demonstrated that PABPN1 shuttles between nucleus and cytoplasm [<a class="bk_pop" href="#opmd.REF.calado.2000.2321">Calado et al 2000</a>] and plays a direct role in the export of poly(A) RNA from the nucleus [<a class="bk_pop" href="#opmd.REF.apponi.2010.1058">Apponi et al 2010</a>]. PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript though the nuclear pore [<a class="bk_pop" href="#opmd.REF.bear.2003.332">Bear et al 2003</a>, <a class="bk_pop" href="#opmd.REF.kerwitz.2003.3705">Kerwitz et al 2003</a>]. Nuclear export of PABPN1 is temperature sensitive, and depends on RNA binding and ongoing transcription. Nuclear import of PABPN1 is an active transportin-mediated process [<a class="bk_pop" href="#opmd.REF.calado.2000.2321">Calado et al 2000</a>].</p><p>Several PABPN1 binding partners have been identified to date, including the heterogeneous family members HNRPA/B, HNRPA1 [<a class="bk_pop" href="#opmd.REF.fan.2003.244">Fan et al 2003</a>] and HNRPC [<a class="bk_pop" href="#opmd.REF.calapez.2002.795">Calapez et al 2002</a>]. By immunoprecipitation, PABPN1 was found to interact with proteins of the cap-binding complex (CBP80, CBP20, and EIF4G) and with proteins involved in <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> decay (Upf2 and Upf3) [<a class="bk_pop" href="#opmd.REF.ishigaki.2001.607">Ishigaki et al 2001</a>]. PABPN1-interacting partners also include HSP40 (DNAJ) and BRG1 [<a class="bk_pop" href="#opmd.REF.kim.2001.1129">Kim et al 2001</a>]. Finally, PABPN1 has been shown to interact with SKIP and to stimulate muscle-specific <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression when overexpressed [<a class="bk_pop" href="#opmd.REF.kim.2001.1129">Kim et al 2001</a>].</p><p>PABPN1 is also implicated in deadenylation via the CCR4-NOT complex that regulates translation of some transcripts [<a class="bk_pop" href="#opmd.REF.chartier.2006.2253">Chartier et al 2006</a>].</p><p>Recently, using the A17.1 OPMD mouse model where mutated PABPN1 is overexpressed [<a class="bk_pop" href="#opmd.REF.de_klerk.2012.9089">de Klerk et al 2012</a>] or RNAi to deplete PABPN1 in mammalian cells [<a class="bk_pop" href="#opmd.REF.jenal.2012.538">Jenal et al 2012</a>, <a class="bk_pop" href="#opmd.REF.beaulieu.2012.e1003078">Beaulieu et al 2012</a>, <a class="bk_pop" href="#opmd.REF.bresson.2013.e1003893">Bresson &#x00026; Conrad 2013</a>], the following new functions of PABPN1 have been uncovered:</p><ul><li class="half_rhythm"><div>Involvement in the choice of alternative polyadenylation sites [<a class="bk_pop" href="#opmd.REF.de_klerk.2012.9089">de Klerk et al 2012</a>, <a class="bk_pop" href="#opmd.REF.jenal.2012.538">Jenal et al 2012</a>]. It has been suggested that PABPN1 binds and masks proximal weak polyadenylation sites, competing with the recruitment of CPSF and enhancing the use of distal canonic polyadenylation sites. Such a shift in the cleavage/polyadenylation site is critical for regulation of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression (length of 3&#x02019;UTR, miRNA target sites).</div></li><li class="half_rhythm"><div>Control of lncRNA (long noncoding RNA) expression [<a class="bk_pop" href="#opmd.REF.beaulieu.2012.e1003078">Beaulieu et al 2012</a>]. An RNAseq approach revealed stabilization of a proportion of lncRNA (16%) in cells depleted for PABPN1. This is a polyadenylation-dependent mechanism with PABPN1-sensitive lncRNAs targeted by the exosome and a RNA helicase.</div></li><li class="half_rhythm"><div><a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> decay [<a class="bk_pop" href="#opmd.REF.bresson.2013.e1003893">Bresson &#x00026; Conrad 2013</a>]. More precisely, the investigators revealed a new function for PABPN1 in a polyadenylation-dependent pathway of RNA decay that targets export-deficient mRNAs. Lastly, it has been suggested that PABPN1-dependent promotion of PAP activity can stimulate nuclear RNA decay.</div></li></ul><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Various hypotheses of a polyalanine toxicity <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> pathogenic mechanism have been proposed [<a class="bk_pop" href="#opmd.REF.brais.1998.164">Brais et al 1998</a>, <a class="bk_pop" href="#opmd.REF.brais.1999.59">Brais et al 1999</a>, <a class="bk_pop" href="#opmd.REF.banerjee.2013.4230">Banerjee et al 2013</a>]. Abnormal aggregation and inefficient protein degradation are some of the gain-of-function pathogenic mechanisms proposed [<a class="bk_pop" href="#opmd.REF.brais.2003.252">Brais 2003</a>]. In these models, PABPN1 is thought to have a pathogenic expanded polyalanine <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> with physical characteristics that cause it to accumulate and interfere with normal cellular processes. However, despite the growing number of studies exploring OPMD pathogenesis, the nature of the underlying pathologic mechanism has yet to be established. More generally, there are suggestions that in addition to having a gain-of-function toxic effect, OPMD aggregates could sequester RNA and proteins including PABPN1 essential for proper cellular function.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Accumulation/aggregation.</b> It was proposed that when more than ten alanines (the normal number) are present in PABPN1, the polyalanine domains polymerize to form stable &#x003b2;-sheets that are resistant to nuclear proteosomal degradation. The polyalanine macromolecules grow over time to form the OPMD PABPN1-containing intranuclear filaments that are seen using electron microscopy [<a class="bk_pop" href="#opmd.REF.tom_.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</a>, <a class="bk_pop" href="#opmd.REF.tom_.1997.s63">Tom&#x000e9; et al 1997</a>, <a class="bk_pop" href="#opmd.REF.calado.2000.2321">Calado et al 2000</a>, <a class="bk_pop" href="#opmd.REF.gidaro.2013.234">Gidaro et al 2013</a>].</div><div class="half_rhythm">Various fusion proteins with long polyalanine domains accumulate as intranuclear inclusions (INI) [<a class="bk_pop" href="#opmd.REF.gaspar.2000.1957">Gaspar et al 2000</a>, <a class="bk_pop" href="#opmd.REF.rankin.2000.15">Rankin et al 2000</a>]. In one transfection experiment, a long 37-Ala-GFP fusion protein caused nuclear inclusion formation and cell death [<a class="bk_pop" href="#opmd.REF.rankin.2000.15">Rankin et al 2000</a>].</div><div class="half_rhythm">Studies with agents that influence this aggregation have been explored and in most cases improve outcome in cellular and mice models of OPMD [<a class="bk_pop" href="#opmd.REF.davies.2005.672">Davies et al 2005</a>, <a class="bk_pop" href="#opmd.REF.wang.2005.3673">Wang et al 2005</a>, <a class="bk_pop" href="#opmd.REF.davies.2006.23">Davies et al 2006</a>, <a class="bk_pop" href="#opmd.REF.verheesen.2006.105">Verheesen et al 2006</a>].</div><div class="half_rhythm">These PABPN1 aggregates are a pathologic hallmark of the disease; however, their exact role in the pathology is still debated. The fact that nuclear aggregates are found in less than 20% of myofiber nuclei in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and unaffected muscle sections of persons with OPMD [<a class="bk_pop" href="#opmd.REF.tom_.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</a>, <a class="bk_pop" href="#opmd.REF.tom_.1997.s63">Tom&#x000e9; et al 1997</a>, <a class="bk_pop" href="#opmd.REF.calado.2000.2321">Calado et al 2000</a>, <a class="bk_pop" href="#opmd.REF.gidaro.2013.234">Gidaro et al 2013</a>] and that both wildtype and expanded PABPN1 proteins can form these aggregates suggest that the presence of PABPN1 aggregates per se may not be sufficient.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Inefficient protein degradation</b></div><ul><li class="half_rhythm"><div>Evidence suggesting that polyalanine oligomers form resistant macromolecules in vivo and in vitro includes the following:</div><ul><li class="half_rhythm"><div class="half_rhythm">Polyalanine oligomers are known to be resistant to protease digestion or chemical degradation [<a class="bk_pop" href="#opmd.REF.forood.1995.7">Forood et al 1995</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Polyalanine oligomers form a &#x003b2;-sheet structure in vitro [<a class="bk_pop" href="#opmd.REF.forood.1995.7">Forood et al 1995</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Polyalanine oligomers containing more than eight alanines in a row form fibrils spontaneously [<a class="bk_pop" href="#opmd.REF.blondelle.1997.8393">Blondelle et al 1997</a>].</div><div class="half_rhythm">PABPN1 molecules in the intranuclear inclusions (INI) of OPMD muscle are more resistant to salt extraction than the protein dispersed in the nucleoplasm [<a class="bk_pop" href="#opmd.REF.calado.2000.2321">Calado et al 2000</a>].</div></li></ul></li><li class="half_rhythm"><div>In addition, a recent cross-species transcriptomic study using drosophila, mouse, and human samples identified deregulation of the ubiquitin-proteasome system (UPS) as the predominant molecular defect in OPMD [<a class="bk_pop" href="#opmd.REF.anvar.2011.15">Anvar et al 2011</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Messenger RNA trapping</b> is another proposed pathophysiologic hypothesis [<a class="bk_pop" href="#opmd.REF.galv_o.2001.191">Galv&#x000e3;o et al 2001</a>]. It has been shown that to aggregate and cause toxicity, PABPN1 has to enter the nuclei [<a class="bk_pop" href="#opmd.REF.abubaker.2005.766">Abu-Baker et al 2005</a>]. Inclusion formation and PABPN1 inclusions have broad and significant impact on the expression of numerous genes, in particular ones that are involved in <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> processing [<a class="bk_pop" href="#opmd.REF.corbeilgirard.2005.551">Corbeil-Girard et al 2005</a>].</div></li></ul></div><div id="opmd.References"><h2 id="_opmd_References_">References</h2><div id="opmd.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="opmd.REF1">Association fran&#x000e7;aise contre les myopathies. Dystrophie Musculaire Oculopharyng&#x000e9;e. Evry, France: Monographies Myoline. 1995.</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF2">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 8-29-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF3">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 8-29-19.</div></li></ul></div><div id="opmd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.abubaker.2005.766">Abu-Baker A, Laganiere S, Fan X, Laganiere J, Brais B, Rouleau GA. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Traffic. </span>2005;<span class="ref-vol">6</span>:766–79.</span> [<a href="/pubmed/16101680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16101680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.abubaker.2013.e821">Abu-Baker A, Laganiere J, Gaudet R, Rochefort D, Brais B, Neri C, Dion PA, Rouleau GA. Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/&#x003b2;-catenin pathway. <span><span class="ref-journal">Cell Death Dis. </span>2013;<span class="ref-vol">4</span>:e821.</span> [<a href="/pmc/articles/PMC3824652/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3824652</span></a>] [<a href="/pubmed/24091664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24091664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.anvar.2011.15">Anvar SY, 't Hoen PA, Venema A, van der Sluijs B, van Engelen B, Snoeck M, Vissing J, Trollet C, Dickson G, Chartier A, Simonelig M, van Ommen GJ, van der Maarel SM, Raz V. Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. <span><span class="ref-journal">Skelet Muscle. </span>2011;<span class="ref-vol">1</span>:15.</span> [<a href="/pmc/articles/PMC3156638/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3156638</span></a>] [<a href="/pubmed/21798095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21798095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.apponi.2010.1058">Apponi LH, Leung SW, Williams KR, Valentini SR, Corbett AH, Pavlath GK. Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. <span><span class="ref-journal">Hum Mol Genet. </span>2010;<span class="ref-vol">19</span>:1058–65.</span> [<a href="/pmc/articles/PMC2830829/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2830829</span></a>] [<a href="/pubmed/20035013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20035013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.askanas.1995.486">Askanas V, Engel WK. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. <span><span class="ref-journal">Curr Opin Rheumatol. </span>1995;<span class="ref-vol">7</span>:486–96.</span> [<a href="/pubmed/8579968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8579968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.banerjee.2013.4230">Banerjee A, Apponi LH, Pavlath GK, Corbett AH. PABPN1: molecular function and muscle disease. <span><span class="ref-journal">FEBS J. </span>2013;<span class="ref-vol">280</span>:4230–50.</span> [<a href="/pmc/articles/PMC3786098/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3786098</span></a>] [<a href="/pubmed/23601051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23601051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.barbeau.1996">Barbeau A. The syndrome of hereditary late-onset ptosis and dysphagia in French Canada. In: K&#x000fc;hn E, ed. <em>Symposium &#x000fc;ber Progressive Muskeldystrophie</em>. Berlin, Germany: Springer-Verlag; 1996:102-9.</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.bear.2003.332">Bear DG, Fomproix N, Soop T, Bjorkroth B, Masich S, Daneholt B. Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore. <span><span class="ref-journal">Exp Cell Res. </span>2003;<span class="ref-vol">286</span>:332–44.</span> [<a href="/pubmed/12749861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12749861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.beaulieu.2012.e1003078">Beaulieu YB, Kleinman CL, Landry-Voyer AM, Majewski J, Bachand F. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1. <span><span class="ref-journal">PLoS Genet. </span>2012;<span class="ref-vol">8</span>:e1003078.</span> [<a href="/pmc/articles/PMC3499365/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3499365</span></a>] [<a href="/pubmed/23166521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23166521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.becher.2001.2437">Becher MW, Morrison L, Davis LE, Maki WC, King MK, Bicknell JM, Reinert BL, Bartolo C, Bear DG. Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. <span><span class="ref-journal">JAMA. </span>2001;<span class="ref-vol">286</span>:2437–40.</span> [<a href="/pubmed/11712939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11712939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.blondelle.1997.8393">Blondelle SE, Forood B, Houghten RA, Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. <span><span class="ref-journal">Biochemistry. </span>1997;<span class="ref-vol">36</span>:8393–400.</span> [<a href="/pubmed/9204887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9204887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.blumen.1999.115">Blumen SC, Brais B, Korczyn AD, Medinsky S, Chapman J, Asherov A, Nisipeanu P, Cod&#x000e8;re F, Bouchard JP, Fardeau M, Tome FM, Rouleau GA. Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. <span><span class="ref-journal">Ann Neurol. </span>1999;<span class="ref-vol">46</span>:115–8.</span> [<a href="/pubmed/10401788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10401788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.blumen.1997.s38">Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Blumen N, Wirguin Y, Khilkevich O, Carasso RL, Korczyn AD. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S38–40.</span> [<a href="/pubmed/9392014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.blumen.1996.1324">Blumen SC, Sadeh M, Korczyn AD, Rouche A, Nisipeanu P, Asherov A, Tome FM. Intranuclear inclusions in oculopharyngeal muscular dystrophy among Bukhara Jews. <span><span class="ref-journal">Neurology. </span>1996;<span class="ref-vol">46</span>:1324–8.</span> [<a href="/pubmed/8628475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8628475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.bouchard.1997.s22">Bouchard JP, Brais B, Brunet D, Gould PV, Rouleau GA. Recent studies on oculopharyngeal muscular dystrophy in Quebec. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S22–9.</span> [<a href="/pubmed/9392011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.bouchard.1992.296">Bouchard JP, Marcoux S, Gosselin F, Pineault D, Rouleau GA. A simple test for the detection of the dysphagia in members of families with oculopharyngeal muscular dystrophy (OPMD). <span><span class="ref-journal">Can J Neurol Sci. </span>1992;<span class="ref-vol">19</span>:296–7.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.brais.2003.252">Brais B. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. <span><span class="ref-journal">Cytogenet Genome Res. </span>2003;<span class="ref-vol">100</span>:252–60.</span> [<a href="/pubmed/14526187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14526187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.brais.1998.164">Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, Mathieu J, Duranceau A, Cod&#x000e8;re F, Fardeau M, Rouleau GA, Korczyn AD. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Nat Genet. </span>1998;<span class="ref-vol">18</span>:164–7.</span> [<a href="/pubmed/9462747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9462747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.brais.1997.s70">Brais B, Bouchard JP, Gosselin F, Xie YG, Fardeau M, Tome FM, Rouleau GA. Using the full power of linkage analysis in 11 French Canadian families to fine map the oculopharyngeal muscular dystrophy gene. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S70–4.</span> [<a href="/pubmed/9392020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.brais.1999.59">Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tome FM. Oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Semin Neurol. </span>1999;<span class="ref-vol">19</span>:59–66.</span> [<a href="/pubmed/10711989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10711989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.brais.1995.429">Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD, Blumen SC, Fardeau M, Tom&#x000e9; FM, Bouchard JP, Rouleau GA. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. <span><span class="ref-journal">Hum Mol Genet. </span>1995;<span class="ref-vol">4</span>:429–34.</span> [<a href="/pubmed/7795598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7795598</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.bresson.2013.e1003893">Bresson SM, Conrad NK. The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay. <span><span class="ref-journal">PLoS Genet. </span>2013;<span class="ref-vol">9</span>:e1003893.</span> [<a href="/pmc/articles/PMC3798265/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3798265</span></a>] [<a href="/pubmed/24146636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24146636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.brunet.1997.s34">Brunet G, Tome FM, Eymard B, Robert JM, Fardeau M. Genealogical study of oculopharyngeal muscular dystrophy in France. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S34–7.</span> [<a href="/pubmed/9392013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.calado.2000.2321">Calado A, Tome FM, Brais B, Rouleau GA, K&#x000fc;hn U, Wahle E, Carmo-Fonseca M. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:2321–8.</span> [<a href="/pubmed/11001936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11001936</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.calapez.2002.795">Calapez A, Pereira HM, Calado A, Braga J, Rino J, Carvalho C, Tavanez JP, Wahle E, Rosa AC, Carmo-Fonseca M. The intranuclear mobility of messenger RNA binding proteins is ATP dependent and temperature sensitive. <span><span class="ref-journal">J Cell Biol. </span>2002;<span class="ref-vol">159</span>:795–805.</span> [<a href="/pmc/articles/PMC2173399/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2173399</span></a>] [<a href="/pubmed/12473688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12473688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.caron.2005.393">Caron MJ, Girard F, Girard DC, Boudreault D, Brais B, Nassif E, Chouinard P, Ruel M, Duranceau A. Cisatracurium pharmacodynamics in patients with oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Anesth Analg. </span>2005;<span class="ref-vol">100</span>:393–7.</span> [<a href="/pubmed/15673864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15673864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.chartier.2006.2253">Chartier A, Benoit B, Simonelig M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. <span><span class="ref-journal">EMBO J. </span>2006;<span class="ref-vol">25</span>:2253–62.</span> [<a href="/pmc/articles/PMC1462976/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1462976</span></a>] [<a href="/pubmed/16642034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16642034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.chartier.2009.1849">Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:1849–59.</span> [<a href="/pubmed/19258344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19258344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.chen.2005.125">Chen JM, Chuzhanova N, Stenson PD, Ferec C, Cooper DN. Complex gene rearrangements caused by serial replication slippage. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">26</span>:125–34.</span> [<a href="/pubmed/15977178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15977178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.cod_re.1993.1">Cod&#x000e8;re F. Oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Can J Ophthalmol. </span>1993;<span class="ref-vol">28</span>:1–2.</span> [<a href="/pubmed/8439856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8439856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.coiffier.2006.218">Coiffier L, P&#x000e9;ri&#x000e9; S, Lafor&#x000ea;t P, Eymard B, St Guily JL. Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Otolaryngol Head Neck Surg. </span>2006;<span class="ref-vol">135</span>:218–22.</span> [<a href="/pubmed/16890071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16890071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.coquet.1990.393">Coquet M, Vital C, Julien J. Presence of inclusion body myositis-like filaments in oculopharyngeal muscular dystrophy. Ultrastructural study of 10 cases. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>1990;<span class="ref-vol">16</span>:393–400.</span> [<a href="/pubmed/2175847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2175847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.corbeilgirard.2005.551">Corbeil-Girard LP, Klein AF, Sasseville AM, Lavoie H, Dicaire MJ, Saint-Denis A, Page M, Duranceau A, Cod&#x000e8;re F, Bouchard JP, Karpati G, Rouleau GA, Massie B, Langelier Y, Brais B. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. <span><span class="ref-journal">Neurobiol Dis. </span>2005;<span class="ref-vol">18</span>:551–67.</span> [<a href="/pubmed/15755682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15755682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.davies.2006.23">Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:23–31.</span> [<a href="/pubmed/16311254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16311254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.davies.2005.672">Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O'Donovan DG, Rubinsztein DC. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. <span><span class="ref-journal">Nat Med. </span>2005;<span class="ref-vol">11</span>:672–7.</span> [<a href="/pubmed/15864313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15864313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.de_klerk.2012.9089">de Klerk E, Venema A, Anvar SY, Goeman JJ, Hu O, Trollet C, Dickson G, den Dunnen JT, van der Maarel SM, Raz V, 't Hoen PA. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. <span><span class="ref-journal">Nucleic Acids Res. </span>2012;<span class="ref-vol">40</span>:9089–101.</span> [<a href="/pmc/articles/PMC3467053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3467053</span></a>] [<a href="/pubmed/22772983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22772983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.dodds.1990.965">Dodds WJ, Logemann JA, Stewart ET. Radiologic assessment of abnormal oral and pharyngeal phases of swallowing. <span><span class="ref-journal">AJR Am J Roentgenol. </span>1990;<span class="ref-vol">154</span>:965–74.</span> [<a href="/pubmed/2108570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2108570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.dubbioso.2012.833">Dubbioso R, Moretta P, Manganelli F, Fiorillo C, Iodice R, Trojano L, Santoro L. Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. <span><span class="ref-journal">J Neurol. </span>2012;<span class="ref-vol">259</span>:833–7.</span> [<a href="/pubmed/21956377" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21956377</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.duranceau.1997.s85">Duranceau A. Cricopharyngeal myotomy in the management of neurogenic and muscular dysphagia. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S85–89.</span> [<a href="/pubmed/9392023" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392023</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.duranceau.1983.825">Duranceau AC, Beauchamp G, Jamieson GG, Barbeau A. Oropharyngeal dysphagia and oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Surg Clin North Am. </span>1983;<span class="ref-vol">63</span>:825–32.</span> [<a href="/pubmed/6351296" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6351296</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.duranceau.1980.33">Duranceau A, Forand MD, Fauteux JP. Surgery in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Am J Surg. </span>1980;<span class="ref-vol">139</span>:33–9.</span> [<a href="/pubmed/7350844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7350844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.fan.2001.2341">Fan X, Dion P, Laganiere J, Brais B, Rouleau GA. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:2341–51.</span> [<a href="/pubmed/11689481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11689481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.fan.2003.244">Fan X, Messaed C, Dion P, Laganiere J, Brais B, Karpati G, Rouleau GA. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Can J Neurol Sci. </span>2003;<span class="ref-vol">30</span>:244–51.</span> [<a href="/pubmed/12945950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12945950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.feit.1998.1732">Feit H, Silbergleit A, Schneider LB, Gutierrez JA, Fitoussi RP, Reyes C, Rouleau GA, Brais B, Jackson CE, Beckmann JS, Seboun E. Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:1732–42.</span> [<a href="/pmc/articles/PMC1377645/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377645</span></a>] [<a href="/pubmed/9837826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9837826</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.forood.1995.7">Forood B, Perez-Paya E, Houghten RA, Blondelle SE. Formation of an extremely stable polyalanine beta-sheet macromolecule. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>1995;<span class="ref-vol">211</span>:7–13.</span> [<a href="/pubmed/7779112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7779112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.fukuhara.1980.229">Fukuhara N, Kumamoto T, Tsubaki T. Rimmed vacuoles. <span><span class="ref-journal">Acta Neuropathol. </span>1980;<span class="ref-vol">51</span>:229–35.</span> [<a href="/pubmed/7445977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7445977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.galv_o.2001.191">Galv&#x000e3;o R, Mendes-Soares L, C&#x000e2;mara J, Jaco I, Carmo-Fonseca M. Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis. <span><span class="ref-journal">Brain Res Bull. </span>2001;<span class="ref-vol">56</span>:191–201.</span> [<a href="/pubmed/11719250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11719250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.gaspar.2000.1957">Gaspar C, Jannatipour M, Dion P, Laganiere J, Sequeiros J, Brais B, Rouleau GA. CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:1957–66.</span> [<a href="/pubmed/10942424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10942424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.gidaro.2013.234">Gidaro T, Negroni E, P&#x000e9;ri&#x000e9; S, Mirabella M, Lain&#x000e9; J, Lacau St Guily J, Butler-Browne G, Mouly V, Trollet C. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2013;<span class="ref-vol">72</span>:234–43.</span> [<a href="/pubmed/23399899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23399899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.goto.1977.600">Goto I, Kanazawa Y, Kobayashi T, Murai Y, Kuroiwa Y. Oculopharyngeal myopathy with distal and cardiomyopathy. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1977;<span class="ref-vol">40</span>:600–7.</span> [<a href="/pmc/articles/PMC492768/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC492768</span></a>] [<a href="/pubmed/903774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 903774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.grewal.1999.1378">Grewal RP, Karkera JD, Grewal RK, Detera-Wadleigh SD. Mutation analysis of oculopharyngeal muscular dystrophy in Hispanic American families. <span><span class="ref-journal">Arch Neurol. </span>1999;<span class="ref-vol">56</span>:1378–81.</span> [<a href="/pubmed/10555658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10555658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.hill.2004.cd004303">Hill M, Hughes T, Milford C. Treatment for swallowing difficulties (dysphagia) in chronic muscle disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2004;<span class="ref-vol">2</span>:CD004303.</span> [<a href="/pubmed/15106246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15106246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.ishigaki.2001.607">Ishigaki Y, Li X, Serin G, Maquat LE. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. <span><span class="ref-journal">Cell. </span>2001;<span class="ref-vol">106</span>:607–17.</span> [<a href="/pubmed/11551508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11551508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.jaspar.1977.272">Jaspar HH, Bastiaensen LA, ter Laak HJ, Joosten EM, Horstink MW, Stadhouders AM. Oculopharyngodistal myopathy with early onset and neurogenic features. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>1977;<span class="ref-vol">80</span>:272–82.</span> [<a href="/pubmed/216518" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 216518</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.jenal.2012.538">Jenal M, Elkon R, Loayza-Puch F, van Haaften G, K&#x000fc;hn U, Menzies FM, Oude Vrielink JA, Bos AJ, Drost J, Rooijers K, Rubinsztein DC, Agami R. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. <span><span class="ref-journal">Cell. </span>2012;<span class="ref-vol">149</span>:538–53.</span> [<a href="/pubmed/22502866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22502866</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.kerwitz.2003.3705">Kerwitz Y, K&#x000fc;hn U, Lilie H, Knoth A, Scheuermann T, Friedrich H, Schwarz E, Wahle E. Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA. <span><span class="ref-journal">EMBO J. </span>2003;<span class="ref-vol">22</span>:3705–14.</span> [<a href="/pmc/articles/PMC165617/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC165617</span></a>] [<a href="/pubmed/12853485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12853485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.kim.2001.1129">Kim YJ, Noguchi S, Hayashi YK, Tsukahara T, Shimizu T, Arahata K. The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1129–39.</span> [<a href="/pubmed/11371506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11371506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.k_hn.2003.16916">K&#x000fc;hn U, Nemeth A, Meyer S, Wahle E. The RNA binding domains of the nuclear poly(A)-binding protein. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:16916–25.</span> [<a href="/pubmed/12637556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12637556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.langmore.1991.678">Langmore SE, Schatz K, Olson N. Endoscopic and videofluoroscopic evaluations of swallowing and aspiration. <span><span class="ref-journal">Ann Otol Rhinol Laryngol. </span>1991;<span class="ref-vol">100</span>:678–81.</span> [<a href="/pubmed/1872520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1872520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.leclerc.1993.283">Leclerc A, Tom&#x000e9; FM, Fardeau M. Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study. <span><span class="ref-journal">Neuromuscul Disord. </span>1993;<span class="ref-vol">3</span>:283–91.</span> [<a href="/pubmed/8268725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8268725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.linoli.1991.325">Linoli G, Tomelleri G, Ghezzi M. Oculopharyngeal muscular dystrophy. Description of a case with involvement of the central nervous system. <span><span class="ref-journal">Pathologica. </span>1991;<span class="ref-vol">83</span>:325–34.</span> [<a href="/pubmed/1923632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1923632</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.manjaly.2012.216">Manjaly JG, Vaughan-Shaw PG, Dale OT, Tyler S, Corlett JC, Frost RA. Cricopharyngeal dilatation for the long-term treatment of dysphagia in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Dysphagia. </span>2012;<span class="ref-vol">27</span>:216–20.</span> [<a href="/pubmed/21805106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21805106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.mathieu.1997.s100">Mathieu J, Lapointe G, Brassard A, Tremblay C, Brais B, Rouleau GA, Bouchard JP. A pilot study on upper oesophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S100–4.</span> [<a href="/pubmed/9392026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.mchorney.2002.97">McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE, Bricker DE. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. <span><span class="ref-journal">Dysphagia. </span>2002;<span class="ref-vol">17</span>:97–114.</span> [<a href="/pubmed/11956835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11956835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.montgomery.1971.986">Montgomery WW, Lynch JP. Oculopharyngeal muscular dystrophy treated by inferior constrictor myotomy. <span><span class="ref-journal">Trans Am Acad Ophthalmol Otolaryngol. </span>1971;<span class="ref-vol">75</span>:986–93.</span> [<a href="/pubmed/5097831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5097831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.nakamoto.2002.474">Nakamoto M, Nakano S, Kawashima S, Ihara M, Nishimura Y, Shinde A, Kakizuka A. Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Arch Neurol. </span>2002;<span class="ref-vol">59</span>:474–7.</span> [<a href="/pubmed/11890856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11890856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.nemeth.1995.4034">Nemeth A, Krause S, Blank D, Jenny A, Jeno P, Lustig A, Wahle E. Isolation of genomic and cDNA clones encoding bovine poly(A) binding protein II. <span><span class="ref-journal">Nucleic Acids Res. </span>1995;<span class="ref-vol">23</span>:4034–41.</span> [<a href="/pmc/articles/PMC307339/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC307339</span></a>] [<a href="/pubmed/7479061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7479061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.p_ri_.1997.s96">P&#x000e9;ri&#x000e9; S, Eymard B, Laccourreye L, Chaussade S, Fardeau M, Lacau St Guily J. Dysphagia in oculopharyngeal muscular dystrophy: a series of 22 French cases. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span> Suppl 1:S96–9.</span> [<a href="/pubmed/9392025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392025</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.p_ri_.1998.1712">P&#x000e9;ri&#x000e9; S, Laccourreye L, Flahault A, Hazebroucq V, Chaussade S, St Guily JL. Role of videoendoscopy in assessment of pharyngeal function in oropharyngeal dysphagia: comparison with videofluoroscopy and manometry. <span><span class="ref-journal">Laryngoscope. </span>1998;<span class="ref-vol">108</span>:1712–6.</span> [<a href="/pubmed/9818831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9818831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.p_ri_.2006.770">P&#x000e9;ri&#x000e9; S, Mamchaoui K, Mouly V, Blot S, Bouazza B, Thornell LE, St Guily JL, Butler-Browne G. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation. <span><span class="ref-journal">Neuromuscul Disord. </span>2006;<span class="ref-vol">16</span>:770–81.</span> [<a href="/pubmed/17005403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17005403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.p_ri_.2014.219">P&#x000e9;ri&#x000e9; S, Trollet C, Mouly V, Vanneaux V, Mamchaoui K, Bouazza B, Marolleau JP, Lafor&#x000ea;t P, Chapon F, Eymard B, Butler-Browne G, Larghero J, St Guily JL. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study. <span><span class="ref-journal">Mol Ther. </span>2014;<span class="ref-vol">22</span>:219–25.</span> [<a href="/pmc/articles/PMC3978797/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3978797</span></a>] [<a href="/pubmed/23831596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23831596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.probst.1982.209">Probst A, Tackmann W, Stoeckli HR, Jerusalem F, Ulrich J. Evidence for a chronic axonal atrophy in oculopharyngeal "muscular dystrophy". <span><span class="ref-journal">Acta Neuropathol. </span>1982;<span class="ref-vol">57</span>:209–16.</span> [<a href="/pubmed/7124348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7124348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.rankin.2000.15">Rankin J, Wyttenbach A, Rubinsztein DC. Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. <span><span class="ref-journal">Biochem J. </span>2000;<span class="ref-vol">348</span>:15–9.</span> [<a href="/pmc/articles/PMC1221030/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1221030</span></a>] [<a href="/pubmed/10794708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10794708</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.raz.2013.516">Raz V, Butler-Browne G, van Engelen B, Brais B. 191st ENMC international workshop: recent advances in oculopharyngeal muscular dystrophy research: from bench to bedside 8-10 June 2012, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2013;<span class="ref-vol">23</span>:516–23.</span> [<a href="/pubmed/23578714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23578714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.restivo.2000.1416">Restivo DA, Marchese RR, Staffieri A, de Grandis D. Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Gastroenterology. </span>2000;<span class="ref-vol">119</span>:1416.</span> [<a href="/pubmed/11185464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11185464</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.rodrigue.1997.s82">Rodrigue D, Molgat YM. Surgical correction of blepharoptosis in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S82–4.</span> [<a href="/pubmed/9392022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.r_egg.2005.574">R&#x000fc;egg S, Lehky Hagen M, Hohl U, Kappos L, Fuhr P, Plasilov M, M&#x000fc;ller H, Heinimann K. Oculopharyngeal muscular dystrophy - an under-diagnosed disorder? <span><span class="ref-journal">Swiss Med Wkly. </span>2005;<span class="ref-vol">135</span>:574–86.</span> [<a href="/pubmed/16333769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16333769</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.salassa.1999.230">Salassa JR. A functional outcome swallowing scale for staging oropharyngeal dysphagia. <span><span class="ref-journal">Dig Dis. </span>1999;<span class="ref-vol">17</span>:230–4.</span> [<a href="/pubmed/10754363" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10754363</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.satoyoshi.1977.89">Satoyoshi E, Kinoshita M. Oculopharyngodistal myopathy. <span><span class="ref-journal">Arch Neurol. </span>1977;<span class="ref-vol">34</span>:89–92.</span> [<a href="/pubmed/836191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 836191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.schober.2001.45">Schober R, Kress W, Grahmann F, Kellermann S, Baum P, G&#x000fc;nzel S, Wagner A. Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Neuropathology. </span>2001;<span class="ref-vol">21</span>:45–52.</span> [<a href="/pubmed/11304042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11304042</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.schotland.1964.433">Schotland DL, Rowland LP. Muscular dystrophy. Features of ocular myopathy, distal myopathy, and myotonic dystrophy. <span><span class="ref-journal">Arch Neurol. </span>1964;<span class="ref-vol">10</span>:433–45.</span> [<a href="/pubmed/14120634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14120634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.scrimgeour.1984.763">Scrimgeour EM, Mastaglia FL. Oculopharyngeal and distal myopathy: a case study from Papua New Guinea. <span><span class="ref-journal">Am J Med Genet. </span>1984;<span class="ref-vol">17</span>:763–71.</span> [<a href="/pubmed/6720743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6720743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.st_guily.1995.723">St Guily JL, Moine A, P&#x000e9;ri&#x000e9; S, Bokowy C, Angelard B, Chaussade S. Role of pharyngeal propulsion as an indicator for upper esophageal sphincter myotomy. <span><span class="ref-journal">Laryngoscope. </span>1995;<span class="ref-vol">105</span>:723–7.</span> [<a href="/pubmed/7603277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7603277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.st_guily.1994.34">St Guily JL, P&#x000e9;ri&#x000e9; S, Willig TN, Chaussade S, Eymard B, Angelard B. Swallowing disorders in muscular diseases: functional assessment and indications of cricopharyngeal myotomy. <span><span class="ref-journal">Ear Nose Throat J. </span>1994;<span class="ref-vol">73</span>:34–40.</span> [<a href="/pubmed/8162870" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8162870</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.tom_.1997.s63">Tom&#x000e9; FM, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:S63–9.</span> [<a href="/pubmed/9392019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9392019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.tom_.1994">Tom&#x000e9; F, Fardeau M. Oculopharyngeal muscular dystrophy. In: <em>Myology</em>. New York, NY: McGraw-Hill; 1994:1233-45.</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.tom_.1980.85">Tom&#x000e9; FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>1980;<span class="ref-vol">49</span>:85–7.</span> [<a href="/pubmed/6243839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6243839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.van_der_sluijs.2004.1499">van der Sluijs BM, ter Laak HJ, Scheffer H, van der Maarel SM, van Engelen BG. Autosomal recessive oculopharyngodistal myopathy: a distinct phenotypical, histological, and genetic entity. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2004;<span class="ref-vol">75</span>:1499–501.</span> [<a href="/pmc/articles/PMC1738751/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1738751</span></a>] [<a href="/pubmed/15377709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15377709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.verheesen.2006.105">Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen GJ, van der Maarel SM, Verrips CT. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:105–11.</span> [<a href="/pubmed/16319127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16319127</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.victor.1962.1267">Victor M, Hayes R, Adams RD. Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids. <span><span class="ref-journal">N Engl J Med. </span>1962;<span class="ref-vol">267</span>:1267–72.</span> [<a href="/pubmed/13997067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13997067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.vita.1983.57">Vita G, Dattola R, Santoro M, Messina C. Familial oculopharyngeal muscular dystrophy with distal spread. <span><span class="ref-journal">J Neurol. </span>1983;<span class="ref-vol">230</span>:57–64.</span> [<a href="/pubmed/6194273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6194273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.wahle.1993.2937">Wahle E, Lustig A, Jeno P, Maurer P. Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides. <span><span class="ref-journal">J Biol Chem. </span>1993;<span class="ref-vol">268</span>:2937–45.</span> [<a href="/pubmed/8428968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8428968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.wahle.1999.277">Wahle E, R&#x000fc;egsegger U. 3'-End processing of pre-mRNA in eukaryotes. <span><span class="ref-journal">FEMS Microbiol Rev. </span>1999;<span class="ref-vol">23</span>:277–95.</span> [<a href="/pubmed/10371034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10371034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.wang.2005.3673">Wang Q, Mosser DD, Bag J. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:3673–84.</span> [<a href="/pubmed/16239242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16239242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.young.1980.413">Young ID, Harper PS. Hereditary distal spinal muscular atrophy with vocal cord paralysis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1980;<span class="ref-vol">43</span>:413–8.</span> [<a href="/pmc/articles/PMC490568/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC490568</span></a>] [<a href="/pubmed/7420092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7420092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opmd.REF.zhao.1999.405">Zhao J, Hyman L, Moore C. Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. <span><span class="ref-journal">Microbiol Mol Biol Rev. </span>1999;<span class="ref-vol">63</span>:405–45.</span> [<a href="/pmc/articles/PMC98971/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC98971</span></a>] [<a href="/pubmed/10357856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10357856</span></a>]</div></li></ul></div></div><div id="opmd.Chapter_Notes"><h2 id="_opmd_Chapter_Notes_">Chapter Notes</h2><div id="opmd.Author_History"><h3>Author History</h3><p>Bernard Brais, MD, MPhil, PhD; H&#x000f4;pital Notre-Dame-CHUM, Montr&#x000e9;al (2001-2014)<br />Gillian Butler-Browne, PhD (2014-present)<br />Teresa Gidaro, MD, PhD (2014-present)<br />Pierre Klein, MSc (2014-present)<br />Jean Lacau St Guily, MD (2014-present)<br />Sophie P&#x000e9;ri&#x000e9;, MD, PhD (2014-present)<br />Guy A Rouleau, MD, PhD; H&#x000f4;pital Notre-Dame-CHUM, Montreal (2001-2014)<br />Capucine Trollet, PhD (2014-present)</p></div><div id="opmd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>20 February 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 June 2006 (ca) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 December 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 March 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>December 2000 (bb) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1126</span><span class="label">PMID: <a href="/pubmed/20301305" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301305</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/oca4/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/opa/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1126&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1126/?report=reader">PubReader</a></li><li><a href="/books/NBK1126/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1126" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1126" style="display:none" title="Cite this Page"><div class="bk_tt">Trollet C, Gidaro T, Klein P, et al. Oculopharyngeal Muscular Dystrophy. 2001 Mar 8 [Updated 2014 Feb 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1126/pdf/Bookshelf_NBK1126.pdf">PDF version of this page</a> (608K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#opmd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#opmd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#opmd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#opmd.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#opmd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#opmd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#opmd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#opmd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#opmd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#opmd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#opmd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8106[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PABPN1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1474332" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1474332" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1474332" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1474332" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30969650" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ptosis Correction</a><span class="source">[StatPearls. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ptosis Correction<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Koka K, Patel BC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">StatPearls. 2019 Jan</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18577654" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.</a><span class="source">[Br J Ophthalmol. 2008]</span><div class="brieflinkpop offscreen_noflow">Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rivera D, Mejia-Lopez H, Pompa-Mera EN, Villanueva-Mendoza C, Nava-Castañeda A, Garnica-Hayashi L, Cuevas-Covarrubias S, Zenteno JC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br J Ophthalmol. 2008 Jul; 92(7):998-1002. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27980005" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Characterization of &lt;i&gt;PABPN1&lt;/i&gt; expansion mutations in a large cohort of Mexican patients with oculopharyngeal muscular dystrophy (OPMD).</a><span class="source">[J Investig Med. 2017]</span><div class="brieflinkpop offscreen_noflow">Characterization of &lt;i&gt;PABPN1&lt;/i&gt; expansion mutations in a large cohort of Mexican patients with oculopharyngeal muscular dystrophy (OPMD).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cruz-Aguilar M, Guerrero-de Ferran C, Tovilla-Canales JL, Nava-Castañeda A, Zenteno JC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Investig Med. 2017 Mar; 65(3):705-708. Epub 2016 Dec 15.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27858728" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling.</a><span class="source">[J Neuromuscul Dis. 2015]</span><div class="brieflinkpop offscreen_noflow">PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Richard P, Trollet C, Gidaro T, Demay L, Brochier G, Malfatti E, Tom FM, Fardeau M, Lafor P, Romero N, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neuromuscul Dis. 2015 Jun 4; 2(2):175-180. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301565" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Central Core Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Central Core Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Malicdan MCV, Nishino I. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301305" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301305" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0417a2dde089116929b99b">Oculopharyngeal Muscular Dystrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Oculopharyngeal Muscular Dystrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:14:59-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BB5D1E04140A10000000001A90099&amp;ncbi_session=CE8BB5D1E0417A21_0425SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1126%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1126&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1126/&amp;ncbi_pagename=Oculopharyngeal Muscular Dystrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BB5D1E0417A21_0425SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>